Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 1-9 (IGKV1-9)
- Target
- IGKV1-9
- Molecular classification
- Immunoglobulin variable region gene, Antibody (component), Other (not a classical receptor, enzyme, etc.)
01
Overview
Immunoglobulin kappa variable 1-9 (IGKV1-9) is a gene segment encoding the variable domain of the kappa light chain in immunoglobulins. The variable domain is essential for the antigen binding specificity of antibodies, as it contributes one part of the antigen binding site in combination with the variable region of the heavy chain. IGKV1-9 undergoes V(D)J recombination in B cells to create antibody diversity, allowing the immune system to recognize a wide array of antigens. It is located within the IGK locus at chromosome 2p11.2 and functions as a component of the immunoglobulin complex produced by B lymphocytes during humoral immune responses[1][3][4]. This gene segment is not a druggable therapeutic target, but it is a fundamental part of the immune system's ability to generate antibodies with diverse antigen specificity through recombination and somatic hypermutation[1][3].
- Other names
- IGKV1-9IGKV19KV109L8
02
Mechanism of action
Not applicable. Drugs do not target this gene directly; antibody generation involves IGKV1-9 as a genetic contributor.
03
Biological functions
Antigen recognitionImmune response (humoral immunity)Somatic recombination (V(D)J rearrangement for diversity)
04
Disease associations
Other (not directly disease-associated, but somatic mutations and clonal expansions in immunoglobulin genes can be implicated in lymphoid malignancies, e.g., leukemia, lymphoma.)
05
Safety considerations
None unique. General immunoglobulin engineering risks apply to all antibody gene segments; no specific safety concerns tied to IGKV1-9 are recorded.
Beyond the preview
Go deeper on Immunoglobulin kappa variable 1-9 (IGKV1-9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin kappa variable 1-9 (IGKV1-9).